title: Dipyridamole for renal phosphate leak in successfully renal transplanted hypophosphatemic patients.
abstract: OBJECTIVE
  Hyphosphatemia can be seen in renal transplant recipients. Hyperparathyroidism, glucocorticoid treatment, renal denervation and impairment of renal tubular phosphate reabsorption are the most common causes of hyphosphatemia in these patients. It is well-known that dipyridamole enhances renal tubular phosphate reabsorption in some clinical conditions. We did not find any information about the effect of dipyridamole in renal transplant recipients (RTRs) with hypophosphatemia. For this reason, we decided to give dipyridamole 11 RTRs with hypophosphatemia.
  
  
  METHODS
  Eleven RTRs whose serum phosphate and creatinine levels were below 2.5 mg/dl and 2 mg/dl, respectively, were included in this study. None of the patients received drugs altering phosphate metabolism and they did not change their routine diets. Urinary phosphate excretion and tubular phosphate reabsorption (TPR) were calculated before and 3 weeks after dipyridamole treatment.
  
  
  RESULTS
  The mean levels of serum-urine (daily) phosphate and TPR before dipyridamole treatment were 1.94 +/- 0.46 mg/dl, 7,187.5 +/- 1,833.49 mg/day and -2.78 +/- 0.62, respectively. After treatment, the mean levels of serum-urine phosphate and TPR were 2.73 +/- 0.46 mg/dl, 4,845.27 +/- 1,138.99 mg/day and -1.48 +/- 0.80, respectively. Serum and urine phosphate levels and TPR were found to be significantly different before and after dipyridamole therapy (p < 0.05).
  
  
  CONCLUSIONS
  Short-term dipyridamole therapy increased TPR and serum phosphate levels and decreased urinary phosphate excretion. We did not observe negative effect on renal functions in these cases. Although the number of the cases included in this study is small, dipyridamole is an effective choice in management of hypophosphatemic RTRs.
authors.affiliation: Department of Nephrology, Faculty of Medicine, Cukurova University, Adana, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Balal
authors.forename: S
authors.initials: S
authors.lastname: Paydas
authors.forename: N
authors.initials: N
authors.lastname: Seyrek
authors.forename: Y
authors.initials: Y
authors.lastname: Sertdemir
authors.forename: I
authors.initials: I
authors.lastname: Karayaylali
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004176:Dipyridamole / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017674:Hypophosphatemia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*
chemical_list: D010710:Phosphates; D010726:Phosphodiesterase Inhibitors; D004176:Dipyridamole